Information Provided By:
Fly News Breaks for July 15, 2019
AMGN, CYTK
Jul 15, 2019 | 12:51 EDT
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $14 price target on Cytokinetics (CYTK) after Amgen (AMGN) completed enrollment of more than 8,200 Heart Failure patients in its Phase III GALACTIC-HF trial of omecamtiv mecarbil. The analyst anticipates an interim GALACTIC-HF efficacy analysis in 2020, with final data likely in 2021.
News For CYTK;AMGN From the Last 2 Days
There are no results for your query CYTK;AMGN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.